INOVIQ EV/FCF

Que fait INOVIQ ? INOVIQ Ltd, listed on the Australian Securities Exchange under the ticker IIQ.AX, is a health care company operating within the health care sector. The company went public through an IPO on April 18, 1991. INOVIQ provides medical services and has developed two products for market: the hTERT ICC test and the EXO-NET Pan-Exosome. The hTERT ICC test is an immunocytochemistry assay designed for detecting human telomerase reverse transcriptase (hTERT) in cytopathology samples. It is used as an adjunct to urine cytology to assist in resolving indeterminate cytology results and identifying patients at higher risk for bladder cancer. EXO-NET Pan-Exosome is a research use only (RUO) tool for capturing exosomes from body fluids such as plasma, urine, and saliva. The company is developing blood tests for the early detection and monitoring of various cancers, including ovarian, breast, and prostate cancers. INOVIQ's focus on cancer diagnostics through innovative testing methods positions it within the biotechnology segment of the health care industry. The company's website is www.inoviq.com, and it operates from an undisclosed location within Australia. No additional details regarding the company's founding year, specific leadership, or financial figures are provided in the available information. INOVIQ est l'une des entreprises les plus populaires sur Eulerpool.